Denali Therapeutics Statistics
Total Valuation
DNLI has a market cap or net worth of $1.97 billion. The enterprise value is $836.82 million.
Important Dates
The next estimated earnings date is Tuesday, May 6, 2025, after market close.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DNLI has 145.22 million shares outstanding. The number of shares has increased by 19.73% in one year.
| Current Share Class | 145.22M |
| Shares Outstanding | 145.22M |
| Shares Change (YoY) | +19.73% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | 4.63% |
| Owned by Institutions (%) | 88.71% |
| Float | 131.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 49.72 |
| PB Ratio | 1.59 |
| P/TBV Ratio | 1.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.46, with a Debt / Equity ratio of 0.04.
| Current Ratio | 8.46 |
| Quick Ratio | 8.16 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,672.93 |
Financial Efficiency
Return on equity (ROE) is -37.40% and return on invested capital (ROIC) is -26.50%.
| Return on Equity (ROE) | -37.40% |
| Return on Assets (ROA) | -24.82% |
| Return on Invested Capital (ROIC) | -26.50% |
| Return on Capital Employed (ROCE) | -39.46% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.00M |
| Employee Count | 422 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DNLI has paid $68,000 in taxes.
| Income Tax | 68,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.75% in the last 52 weeks. The beta is 1.54, so DNLI's price volatility has been higher than the market average.
| Beta (5Y) | 1.54 |
| 52-Week Price Change | -33.75% |
| 50-Day Moving Average | 18.89 |
| 200-Day Moving Average | 23.19 |
| Relative Strength Index (RSI) | 34.19 |
| Average Volume (20 Days) | 1,352,944 |
Short Selling Information
The latest short interest is 10.51 million, so 7.23% of the outstanding shares have been sold short.
| Short Interest | 10.51M |
| Short Previous Month | 8.89M |
| Short % of Shares Out | 7.23% |
| Short % of Float | 8.00% |
| Short Ratio (days to cover) | 8.02 |
Income Statement
| Revenue | n/a |
| Gross Profit | -396.44M |
| Operating Income | -501.88M |
| Pretax Income | -419.62M |
| Net Income | -422.77M |
| EBITDA | -500.79M |
| EBIT | -501.88M |
| Earnings Per Share (EPS) | -$2.57 |
Full Income StatementBalance Sheet
The company has $832.33 million in cash and $54.32 million in debt, giving a net cash position of $1.14 billion or $7.83 per share.
| Cash & Cash Equivalents | 832.33M |
| Total Debt | 54.32M |
| Net Cash | 1.14B |
| Net Cash Per Share | $7.83 |
| Equity (Book Value) | 1.23B |
| Book Value Per Share | 8.53 |
| Working Capital | 762.23M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$347.69 million and capital expenditures -$15.91 million, giving a free cash flow of -$363.61 million.
| Operating Cash Flow | -347.69M |
| Capital Expenditures | -15.91M |
| Free Cash Flow | -363.61M |
| FCF Per Share | -$2.50 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |